GH1 and hypopituitarism: In conclusion, in a real-life setting such as the Italian HypoCCS study, increased IGF-I SDS, decreased LDL-cholesterol, more robust diagnostic tests and more severe causes of hypopituitarism (i.e. craniopharyngioma) are associated with a longer term duration of GH therapy.